
Eli Lilly Crushes Expectations, Raises 2026 Outlook on GLP-1 Dominance
Eli Lilly beat Q1 earnings expectations and raised full-year guidance, driven by blockbuster demand for weight-loss drugs Mounjaro and Zepbound.
LLYearningsacquisitions









Investing.com··Ali Merchant


